Biotech

All Articles

Recursion's mind disease trial shows little proof of efficacy

.Recursion has stumbled by means of an early test of its tech-enabled strategy to medicine explorati...

Acepodia, Pfizer click with each other for chemistry-based cell treatment

.Contact it an instance of really good chemistry: Acepodia, a biotech based upon Nobel Prize-winning...

Praxis epilepsy medication minimizes seizures in period 2 hearing

.Praxis Precision Medicines has racked up another midphase win in epilepsy this year, with its sodiu...

Three execs surrender as Dyne articles mixed information for DMD prospect

.After running away a clinical grip a number of years back, Dyne Rehab has disclosed brand-new perio...

Arrowhead fires off period 3 data in unusual metabolic condition in front of market encounter Ionis

.Arrowhead Pharmaceuticals has revealed its hand in advance of a possible showdown with Ionis, publi...

Pfizer, Valneva reveal lyme condition try reliable for second booster

.Pfizer as well as Valneva may possess regarding two additional years to stand by before they create...

Fierce Biotech Managing Editor Ayla Ellison Talks Shop with Michelle Benz on the Future of Biotech.

.Let's dive into a discussion with Ayla Ellison, Intense Biotech Editor-in-Chief and also Michelle B...

New information demonstrate how Bayer's asundexian stopped working to stop movements

.Bayer suspended the stage 3 test for its own aspect XIa prevention asundexian late in 2015 after th...

Sanofi's tolebrutinib neglects 2 of 3 late-stage MS trials

.Sanofi is still bented on taking its a number of sclerosis (MS) med tolebrutinib to the FDA, manage...

Galapagos' stock up as fund reveals intent to mold its own progression

.Galapagos is happening under additional pressure from entrepreneurs. Having created a 9.9% risk in ...